

FORM PTO-1390 (Modified) (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER <b>RTSP-0265</b>	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR <b>10/019595</b>	
INTERNATIONAL APPLICATION NO <b>PCT/US00/19822</b>		INTERNATIONAL FILING DATE <b>20 July 2000</b>		PRIORITY DATE CLAIMED <b>23 July 1999</b>	
TITLE OF INVENTION <b>ANTISENSE MODULATION OF MEKK5 EXPRESSION</b>					
APPLICANT(S) FOR DO/EO/US <b>MONIA, Brett P., GAARDE, William A. and COWSERT, Lex M.</b>					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.</li> <li>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</li> <li>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</li> <li>12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</li> </ol>					
<b>Items 13 to 20 below concern document(s) or information included:</b>					
<ol style="list-style-type: none"> <li>13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>15. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li> <li>16. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>17. <input type="checkbox"/> A substitute specification.</li> <li>18. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>19. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</li> <li>20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4)</li> <li>22. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail</li> <li>23. <input checked="" type="checkbox"/> Other items or information:  <p><b>1) Courtesy copy of the International Application; 2) Statement to support filing and submission in accordance with 37 CFR 1.821-1.825; 3) Paper and Disk copy of Amended Sequence Listing; 4) Return Postcard.</b></p> </li> </ol>					

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.492) <b>10/019595</b>		INTERNATIONAL APPLICATION NO. <b>PCT/US00/19822</b>		ATTORNEY'S DOCKET NUMBER <b>RTSP-0265</b>	
--	--	---	--	---	--

24. The following fees are submitted: <b>BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :</b> <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... <b>\$1040.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$890.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$740.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$710.00</b> <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$100.00</b> <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>CALCULATIONS PTO USE ONLY</b>	
				<b>\$100.00</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				<b>\$0.00</b>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	20 - 20 =	0	x \$18.00	<b>\$0.00</b>	
Independent claims	1 - 3 =	0	x \$84.00	<b>\$0.00</b>	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				<b>\$0.00</b>	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$100.00</b>	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				<b>\$50.00</b>	
<b>SUBTOTAL =</b>				<b>\$50.00</b>	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				<b>\$0.00</b>	
<b>TOTAL NATIONAL FEE =</b>				<b>\$50.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				<b>\$0.00</b>	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$50.00</b>	
				Amount to be: refunded	\$
				charged	\$

a. ☐ A check in the amount of \_\_\_\_\_ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 50-1619 in the amount of \$50.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1619. A duplicate copy of this sheet is enclosed.


d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jane Massey Licata, Registration No. 32,257  
 Kathleen A. Tyrrell, Registration No. 38,350  
 Licata & Tyrrell P.C.  
 66 East Main Street  
 Marlton, New Jersey 08053

Tel: 856-810-1515  
 Fax: 856-810-1454

  
 SIGNATURE  
**Kathleen A. Tyrrell**  
 NAME  
**38,350**  
 REGISTRATION NUMBER  
**December 26, 2001**  
 DATE

10/0195952202

531 Rec'd PCT 26 DEC 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#4/a

Attorney Docket No.: RTSP-0265  
Inventors: Monia et al.  
Serial No.: Not yet assigned  
Filing Date: Herewith  
Examiner: Not yet assigned  
Group Art Unit: Not yet assigned  
Title: ANTISENSE MODULATION OF MEKKS EXPRESSION

"Express Mail" Label No. EV017478069US  
Date of Deposit December 26, 2001

I hereby certify that this paper is being deposited  
with the United States Postal Service "Express Mail  
Post Office to Addressee" service under 37 CFR 1.10  
on the date indicated above and is addressed to the  
Assistant Commissioner for Patents, Washington,  
D.C. 20231

By Kathleen A. Tyrrell  
Typed Name Kathleen A. Tyrrell, Reg. No. 38,350

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

PRELIMINARY AMENDMENT


It is respectfully requested that the Sequence Listing of the  
instant specification be deleted and replaced with the amended  
Sequence Listing provided herewith. A paper copy and a CRF copy of  
the amended Sequence Listing are provided herewith.

The replacement Sequence Listing has been amended to conform  
with the current Sequence Listing Rules.

Attorney Docket No.: RTSP-0265  
Inventors: Monia et al.  
Serial No.: Not yet assigned  
Filing Date: Herewith  
Page 2

No new matter has been added by this amendment.

Respectfully submitted,



Kathleen A. Tyrrell  
Registration No. 38,350

Date: December 26, 2001

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515

-1-

**ANTISENSE MODULATION OF MEKK5 EXPRESSION****FIELD OF THE INVENTION**

The present invention provides compositions and  
5 methods for modulating the expression of MEKK5. In  
particular, this invention relates to antisense compounds,  
particularly oligonucleotides, specifically hybridizable  
with nucleic acids encoding human MEKK5. Such  
oligonucleotides have been shown to modulate the expression  
10 of MEKK5.

**BACKGROUND OF THE INVENTION**

One of the principal mechanisms by which cellular  
regulation is effected is through the transduction of  
extracellular signals across the membrane that in turn  
15 modulate biochemical pathways within the cell. Protein  
phosphorylation represents one course by which  
intracellular signals are propagated from molecule to  
molecule resulting finally in a cellular response. These  
signal transduction cascades are highly regulated and often  
20 overlapping as evidenced by the existence of many protein  
kinases as well as protein phosphatases. It is currently  
believed that a number of disease states and/or disorders  
are a result of either aberrant expression or functional  
mutations in the molecular components of kinase cascades.  
25 Consequently, considerable attention has been devoted to  
the characterization of these proteins.

Nearly all cell surface receptors use one or more of  
the mitogen-activated protein kinase (MAP kinase) cascades  
during signal transduction. Three distinct subgroups of  
30 the MAP kinases have been identified and each of these  
consists of a specific module of downstream kinases. These  
subgroups consist of the extracellular signal-regulated  
protein kinase pathway (MAPK/ERK kinases), the Jun N-  
terminal kinase/Stress activated protein kinase pathway  
35 (JNK/SAPK kinases) and the p38 kinase pathway. The

-2-

MAPK/ERK pathway is activated by signals emanating from growth factor stimulation while the p38 pathway is activated by high osmolarity, lipopolysaccharides, tumor necrosis factor- $\alpha$ , and interleukin-1 (Moriguchi et al.,  
5 *Adv. Pharmacol.*, 1996, 36, 121-137). The JNK/SAPK pathway was originally identified as an oncogene- and ultraviolet light-stimulated kinase pathway but is now known to be activated by growth factors, cytokines and T-cell costimulation (Moriguchi et al., *Adv. Pharmacol.*, 1996, 36,  
10 121-137; Su and Karin, *Curr. Opin. Immunol.*, 1996, 8, 402-411).

MEKK5 (also known as mitogen-activated protein kinase kinase kinase 5, MEK kinase 5, MAP/ERK kinase kinase 5 and ASK1 or apoptosis signal-regulating kinase 1) is a dual  
15 specific serine/threonine kinase that functions to mediate cellular responses to mitogenic stimuli by activating both the JNK/SAPK and the p38 modules of MAP kinase cascades (Ichijo et al., *Science*, 1997, 275, 90-94; Wang et al., *J. Biol. Chem.*, 1996, 271, 31607-31611). The protein is  
20 ubiquitously expressed with the highest expression in the heart, pancreas, testis and ovaries (Ichijo et al., *Science*, 1997, 275, 90-94).

It is currently believed that MEKK5 plays a critical role in the regulation of apoptosis or programmed cell  
25 death by interacting with other proteins in this cascade and by phosphorylating downstream targets such as MKK3 and SEK1. Consequently, MEKK5 activity has been associated with pathologic conditions such as inflammation and wound healing (Funato et al., *Lab. Invest.*, 1998, 78, 477-483;  
30 Nishitoh et al., *Mol. Cell.*, 1998, 2, 389-395).

Recently it was demonstrated that the tumor necrosis factor  $\alpha$ -induced activation and dimerization of MEKK5 is mediated by reactive oxygen species (ROS) (Gotoh and Cooper, *J. Biol. Chem.*, 1998, 273, 17477-17482).

- 3 -

Subsequently, it was shown that thioredoxin, a reduction/oxidation regulatory protein, associates with MEKK5 and inhibits MEKK5 kinase activity and MEKK5-dependent apoptosis (Saitoh et al., *Embo. J.*, 1998, 17, 2596-2606).

MEKK5 also participates in another apoptosis related signaling cascade involving the modulation of transcription factors. MEKK5 was shown to be activated by the adapter protein, Daxx. This protein enhances Fas-induced apoptosis  
10 by activating the JNK/SAPK kinases culminating in the phosphorylation of transcription factors (Chang et al., *Science*, 1998, 281, 1860-1863).

United States Patent No. 5,981,265 (Johnson) claims methods for regulating MEKK protein activity in a cell comprising transforming or transfecting the cell with a nucleic acid molecule encoding an MEKK protein such that MEKK protein activity in the cell is regulated, wherein the nucleic acid molecule is capable of hybridizing under stringent conditions to a nucleic acid molecule encoding MEKK1, MEKK2, MEKK3, MEKK4, MEKK5 or MEKK6.

Oligonucleotides for use in antisense, and triplex formation, as ribozymes, probes or primers and in other applications are generally disclosed.

United States Patent No. 6,074,861 (Johnson) generally  
25 discloses isolated nucleic acid molecules capable of  
hybridizing under stringent conditions with an MEKK protein  
gene encoding an MEKK protein. Oligonucleotides for use in  
antisense, and triplex formation, as ribozymes, probes or  
primers and in other applications are generally disclosed.

30       Currently, there are no known therapeutic agents which  
effectively inhibit the synthesis of MEKK5 and to date,  
strategies aimed at modulating MEKK5 function have involved  
the use of antibodies, dominant negative and dominant  
active mutants of the protein. Consequently, there remains  
35 a long felt need for agents capable of effectively

-4-

inhibiting MEKK5 function.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of  
5 therapeutic, diagnostic, and research applications for the modulation of MEKK5 expression.

#### **SUMMARY OF THE INVENTION**

The present invention is directed to antisense compounds, particularly oligonucleotides, which are  
10 targeted to a nucleic acid encoding MEKK5, and which modulate the expression of MEKK5. Pharmaceutical and other compositions comprising the antisense compounds of the invention are also provided. Further provided are methods of modulating the expression of MEKK5 in cells or tissues  
15 comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression  
20 of MEKK5 by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

#### **DETAILED DESCRIPTION OF THE INVENTION**

The present invention employs oligomeric antisense  
25 compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding MEKK5, ultimately modulating the amount of MEKK5 produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids  
30 encoding MEKK5. As used herein, the terms "target nucleic acid" and "nucleic acid encoding MEKK5" encompass DNA encoding MEKK5, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound  
35 with its target nucleic acid interferes with the normal



-5-

function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of MEKK5. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding MEKK5. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the

-6-

gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the

5 "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and

10 "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more

15 alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the

20 codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding MEKK5, regardless of the sequence(s) of such codons.

It is also known in the art that a translation

25 termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of

30 such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene

35 that encompasses from about 25 to about 50 contiguous

-7-

nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It

-8-

has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified,  
5 oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization"  
10 means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds.  
15 "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide  
20 and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen  
25 bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is  
30 understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule  
35 interferes with the normal function of the target DNA or

-9-

RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e.,  
5 under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

Antisense compounds are commonly used as research  
10 reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to  
15 distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic  
20 uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus  
25 established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

In the context of this invention, the term  
30 "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as  
35 oligonucleotides having non-naturally-occurring portions

-10-

which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 25 nucleobases. As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

-11-

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

-12-

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenediazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular



-13-

an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, 1991, 254, 1497-1500.

10 Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular  $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$ ,  $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$  [known as a methylene (methylimino) or MMI backbone],  $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$ ,  
15  $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$  and  $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$  [wherein the native phosphodiester backbone is represented as  $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$  of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having  
20 morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F;  
25 O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted  $\text{C}_1$  to  $\text{C}_{10}$  alkyl or  $\text{C}_2$  to  $\text{C}_{10}$  alkenyl and alkynyl. Particularly preferred are  $\text{O}[(\text{CH}_2)_n\text{O}]_m\text{CH}_3$ ,  $\text{O}(\text{CH}_2)_n\text{OCH}_3$ ,  $\text{O}(\text{CH}_2)_n\text{NH}_2$ ,  $\text{O}(\text{CH}_2)_n\text{CH}_3$ ,  $\text{O}(\text{CH}_2)_n\text{ONH}_2$ ,  
30 and  $\text{O}(\text{CH}_2)_n\text{ON}[(\text{CH}_2)_n\text{CH}_3]_2$ , where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position:  $\text{C}_1$  to  $\text{C}_{10}$  lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH,  $\text{SCH}_3$ , OCN, Cl, Br, CN,  $\text{CF}_3$ ,  $\text{OCF}_3$ ,  $\text{SOCH}_3$ ,  $\text{SO}_2\text{CH}_3$ ,  
35  $\text{ONO}_2$ ,  $\text{NO}_2$ ,  $\text{N}_3$ ,  $\text{NH}_2$ , heterocycloalkyl, heterocycloalkaryl,

-14-

aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminooxyethoxy, i.e., a O(CH<sub>2</sub>)<sub>2</sub>ON(CH<sub>3</sub>)<sub>2</sub> group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>2</sub>)<sub>2</sub>, also described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O-CH<sub>3</sub>), 2'-aminopropoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or

-15-

substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other  
5 synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-  
10 thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl  
15 and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in United States Patent No.  
20 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S.,  
25 Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines,  
30 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds.,

-16-

*Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

5 Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273;  
10 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United  
15 States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the  
20 oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989,  
25 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et  
30 al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259, 327-330; Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a phospholipid, e.g., di-

-17-

hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a polyamine or a  
5 polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229-237), or an octadecylamine or hexylamino-  
10 carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923-937).

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105;  
15 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582;  
20 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481;  
25 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given  
30 compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds.

-18-

"Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.:

5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878;  
5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355;

-19-

5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S.:  
5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291;  
5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330;  
4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170;  
5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978;  
5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259;  
5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such

-20-

esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the  
5 disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that  
10 is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE  
15 [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to  
20 physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are  
25 formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are  
N,N'-dibenzylethylenediamine, chloroprocaine, choline,  
30 diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a  
35 sufficient amount of the desired base to produce the salt



-21-

in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylemaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfoic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic

-22-

acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of  
5 compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are  
10 also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as  
15 spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric  
20 acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid,  
25 polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and  
30 as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of MEKK5 is treated by administering antisense compounds in accordance with this invention. The compounds  
35 of the invention can be utilized in pharmaceutical

-23-

compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to  
5 prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding MEKK5, enabling  
10 sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding MEKK5 can be detected by means known in the art. Such means may include conjugation of an enzyme to the  
15 oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of MEKK5 in a sample may also be prepared.

The present invention also includes pharmaceutical  
20 compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be  
25 treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and  
30 transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at  
35 least one 2'-O-methoxyethyl modification are believed to be

-24-

particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, 5 sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions and formulations for oral administration 10 include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions and formulations for parenteral, 15 intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

20 Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying 25 solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such 30 techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided 35 solid carriers or both, and then, if necessary, shaping the

- 25 -

product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

## Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1  $\mu\text{m}$  in diameter. (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New

-26-

York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases

5 intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a

10 water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to

15 the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed.

20 Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple

25 binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o

30 emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this

35 form through the means of emulsifiers or the viscosity of

-27-

the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be

5 incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker

10 (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger,

15 in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are

20 typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the

25 preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker,

30 Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o

-28-

emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous  
5 preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as  
10 carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants,  
15 hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel  
20 Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth),  
25 cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming  
30 strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides  
35 that may readily support the growth of microbes, these



-29-

formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable

-30-

liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically  
5 dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically  
10 clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions  
15 commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used  
20 and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams  
25 has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245;  
30 Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of

-31-

thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-  
5 ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate  
10 (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into  
15 the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art.  
20 The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355,  
25 Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.  
30 Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides  
35 (Constantinides et al., *Pharmaceutical Research*, 1994, 11,

-32-

1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*,  
1993, 13, 205). Microemulsions afford advantages of  
improved drug solubilization, protection of drug from  
enzymatic hydrolysis, possible enhancement of drug  
5 absorption due to surfactant-induced alterations in  
membrane fluidity and permeability, ease of preparation,  
ease of oral administration over solid dosage forms,  
improved clinical potency, and decreased toxicity  
(Constantinides et al., *Pharmaceutical Research*, 1994, 11,  
10 1385; Ho et al., *J. Pharm. Sci.*, 1996, 85, 138-143). Often  
microemulsions may form spontaneously when their components  
are brought together at ambient temperature. This may be  
particularly advantageous when formulating thermolabile  
drugs, peptides or oligonucleotides. Microemulsions have  
15 also been effective in the transdermal delivery of active  
components in both cosmetic and pharmaceutical  
applications. It is expected that the microemulsion  
compositions and formulations of the present invention will  
facilitate the increased systemic absorption of  
20 oligonucleotides and nucleic acids from the  
gastrointestinal tract, as well as improve the local  
cellular uptake of oligonucleotides and nucleic acids  
within the gastrointestinal tract, vagina, buccal cavity  
and other areas of administration.

25 Microemulsions of the present invention may also  
contain additional components and additives such as  
sorbitan monostearate (Grill 3), Labrasol, and penetration  
enhancers to improve the properties of the formulation and  
to enhance the absorption of the oligonucleotides and  
30 nucleic acids of the present invention. Penetration  
enhancers used in the microemulsions of the present  
invention may be classified as belonging to one of five  
broad categories - surfactants, fatty acids, bile salts,  
chelating agents, and non-chelating non-surfactants (Lee et  
35 al., *Critical Reviews in Therapeutic Drug Carrier Systems*,

-33-

1991, p. 92). Each of these classes has been discussed above.

#### Liposomes

There are many organized surfactant structures besides  
5 microemulsions that have been studied and used for the  
formulation of drugs. These include monolayers, micelles,  
bilayers and vesicles. Vesicles, such as liposomes, have  
attracted great interest because of their specificity and  
the duration of action they offer from the standpoint of  
10 drug delivery. As used in the present invention, the term  
"liposome" means a vesicle composed of amphiphilic lipids  
arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles  
which have a membrane formed from a lipophilic material and  
15 an aqueous interior. The aqueous portion contains the  
composition to be delivered. Cationic liposomes possess  
the advantage of being able to fuse to the cell wall. Non-  
cationic liposomes, although not able to fuse as  
efficiently with the cell wall, are taken up by macrophages  
20 *in vivo*.

In order to cross intact mammalian skin, lipid  
vesicles must pass through a series of fine pores, each  
with a diameter less than 50 nm, under the influence of a  
suitable transdermal gradient. Therefore, it is desirable  
25 to use a liposome which is highly deformable and able to  
pass through such fine pores.

Further advantages of liposomes include; liposomes  
obtained from natural phospholipids are biocompatible and  
biodegradable; liposomes can incorporate a wide range of  
30 water and lipid soluble drugs; liposomes can protect  
encapsulated drugs in their internal compartments from  
metabolism and degradation (Rosoff, in *Pharmaceutical  
Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988,  
Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245).  
35 Important considerations in the preparation of liposome

-34-

formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, 1987, 147, 980-985).

35 Non-ionic liposomal systems have also been examined to

-36-

determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl  
5 dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems  
10 were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, 1994, 4, 6, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to  
15 liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming  
20 lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G<sub>M1</sub>, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art  
25 that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES)  
30 (Allen et al., *FEBS Letters*, 1987, 223, 42; Wu et al., *Cancer Research*, 1993, 53, 3765). Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, 1987, 507, 64) reported the ability of monosialoganglioside G<sub>M1</sub>,



-37-

galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci. U.S.A.*, 1988, 85, 6949). U.S. Patent No. 4,837,028 and WO 5 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G<sub>M1</sub> or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn- 10 dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (*Bull. 15 Chem. Soc. Jpn.*, 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C<sub>12</sub>15G, that contains a PEG moiety. Illum et al. (*FEBS Lett.*, 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood 20 half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klivanov et al. (*FEBS Lett.*, 1990, 268, 235) described experiments demonstrating that 25 liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, 1990, 1029, 91) extended such observations to other PEG-derivatized phospholipids, 30 e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome

-38-

compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To

-39-

make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of  
5 serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The  
10 most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for  
15 categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants  
20 find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol  
25 esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The  
30 polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include  
35 carboxylates such as soaps, acyl lactylates, acyl amides of

-40-

amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important  
5 members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include  
10 quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is  
15 classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in  
20 *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

#### Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient  
25 delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic  
30 drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

35 Penetration enhancers may be classified as belonging

-41-

to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above  
5 mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution,  
10 reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration  
15 enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm.*  
20 *Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid,  
25 linolenic acid, dicaprates, tricaprates, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprates, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C<sub>1-10</sub> alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate,  
30 laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990,

-42-

7, 1-33; El Hariri et al., J. Pharm. Pharmacol., 1992, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydrofusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*, 1990, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that

- 43 -

absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, 1993, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Buur et al., *J. Control Rel.*, 1990, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacycloalkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, 1987, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S.

-44-

Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

5 Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

#### 10 Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (i.e., does  
15 not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation.

20 The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition  
25 between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-  
30 4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

#### Excipients

In contrast to a carrier compound, a "pharmaceutical  
35 carrier" or "excipient" is a pharmaceutically acceptable



-45-

solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically

acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

#### Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide

-47-

pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include, but are not limited to, anticancer drugs such as daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 1206-1228). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

25 In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with

-48-

the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on  $EC_{50}$ s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

#### EXAMPLES

##### Example 1

#### 30 Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2'-alkoxy amidites

2'-Deoxy and 2'-methoxy beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA). Other 2'-O-alkoxy substituted nucleoside amidites are

-49-

prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., *Nucleic Acids Research*, 1993, 21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA).

#### 2'-Fluoro amidites

##### 2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*, 1993, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S<sub>N</sub>2-displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

##### 2'-Fluorodeoxyguanosine

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting

-50-

material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected

5 arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

10 **2'-Fluorouridine**

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard  
15 procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

**2'-Fluorodeoxycytidine**

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by  
20 selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

**2'-O-(2-Methoxyethyl) modified amidites**

2'-O-Methoxyethyl-substituted nucleoside amidites are  
25 prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

**2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]**

5-Methyluridine (ribosylthymine, commercially  
30 available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner.

-51-

After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4°C).

#### 2'-O-Methoxyethyl-5-methyluridine

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH<sub>3</sub>CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH<sub>2</sub>Cl<sub>2</sub>/acetone/MeOH (20:5:3) containing 0.5% Et<sub>3</sub>NH. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

#### 2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was

-52-

co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH<sub>3</sub>CN (200 mL). The residue was dissolved in CHCl<sub>3</sub> (1.5 L) and extracted with 2x500 mL of saturated NaHCO<sub>3</sub> and 2x500 mL of saturated NaCl. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5:5:1) containing 0.5% Et<sub>3</sub>NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl<sub>3</sub> (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl<sub>3</sub>. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product).



-53-

The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

5        **3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine**

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH<sub>3</sub>CN (700 mL) and set  
10 aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH<sub>3</sub>CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl<sub>3</sub> was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture  
15 stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The  
20 residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO<sub>3</sub> and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

25        **2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH<sub>4</sub>OH (30 mL) was stirred at room  
30 temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH<sub>3</sub> gas was added and the vessel heated  
35 to 100°C for 2 hours (TLC showed complete conversion). The

-54-

vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

**N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in  $\text{CHCl}_3$  (700 mL) and extracted with saturated  $\text{NaHCO}_3$  (2x300 mL) and saturated NaCl (2x300 mL), dried over  $\text{MgSO}_4$  and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/hexane (1:1) containing 0.5%  $\text{Et}_3\text{NH}$  as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

**N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite**

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in  $\text{CH}_2\text{Cl}_2$  (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated  $\text{NaHCO}_3$  (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with  $\text{CH}_2\text{Cl}_2$  (300 mL), and the extracts were combined, dried over  $\text{MgSO}_4$  and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc/hexane (3:1) as the eluting solvent. The pure

-55-

fractions were combined to give 90.6 g (87%) of the title compound.

**2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites**

5        **2'-(Dimethylaminooxyethoxy) nucleoside amidites**

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside  
10 amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

15        **5'-O-tert-Butyldiphenylsilyl-O<sup>2</sup>-2'-anhydro-5-methyluridine**

O<sup>2</sup>-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and  
20 with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (R<sub>f</sub> 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under  
25 reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1  
30 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC

-56-

and NMR were consistent with pure product.

**5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine**

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl-O<sup>2</sup>-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

**2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine**

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-

-57-

methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over  $P_2O_5$  under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry  $CH_2Cl_2$  (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate was washed with ice cold  $CH_2Cl_2$  and the combined organic phase was washed with water, brine and dried over anhydrous  $Na_2SO_4$ . The solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get 5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine as white foam (1.95 g, 78%).

-58-

**5'-O-tert-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine**

5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) was added to this solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>). Aqueous NaHCO<sub>3</sub> solution (5%, 10mL) was added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO<sub>3</sub> (25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to get 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

**2'-O-(dimethylaminoxyethyl)-5-methyluridine**

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-

-59-

dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>). Solvent was removed under vacuum and the residue placed on a flash column and  
5 eluted with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to get 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%).

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine  
2'-O-(dimethylaminoxyethyl)-5-methyluridine (750mg,  
10 2.17mmol) was dried over P<sub>2</sub>O<sub>5</sub> under high vacuum overnight at 40°C. It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg,  
15 2.60mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (containing a few drops of pyridine) to get 5'-O-DMT-  
20 2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine  
25 (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over P<sub>2</sub>O<sub>5</sub> under high vacuum overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-  
30 N,N,N<sup>1</sup>,N<sup>1</sup>-tetraisopropylphosphoramidite (2.12mL, 6.08mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was

-60-

dissolved in ethyl acetate (70mL) and washed with 5% aqueous  $\text{NaHCO}_3$  (40mL). Ethyl acetate layer was dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-  
5 2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

**2'-(Aminooxyethoxy) nucleoside amidites**

2'-(Aminooxyethoxy) nucleoside amidites [also known in  
10 the art as 2'-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

15 **N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine  
20 riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-  
25 O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-  
30 diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via



-61-

a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

**2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites**

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>2</sub>)<sub>2</sub>, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

**2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine**

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O<sup>2</sup>-, 2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed, placed in an oil bath and heated to 155°C for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

-62-

**5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]]-5-methyl uridine**

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2x200 mL). The combined CH<sub>2</sub>Cl<sub>2</sub> layers are washed with saturated NaHCO<sub>3</sub> solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using MeOH:CH<sub>2</sub>Cl<sub>2</sub>:Et<sub>3</sub>N (20:1, v/v, with 1% triethylamine) gives the title compound.

**5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite**

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

**Example 2**

**Oligonucleotide synthesis**

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-

-63-

benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and  
5 deblocking in concentrated ammonium hydroxide at 55°C (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by  
10 reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are  
15 prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

20 Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are  
25 prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

30 Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

### Example 3

#### Oligonucleoside Synthesis

35 Methylene-methylimino linked oligonucleosides, also

-64-

identified as MMI linked oligonucleosides, methylenedi-methylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked  
5 oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023,  
10 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

15 Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

#### Example 4

##### PNA Synthesis

20 Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 5-23. They may also be prepared in accordance  
25 with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

#### Example 5

##### Synthesis of Chimeric Oligonucleotides

Chimeric oligonucleotides, oligonucleosides or mixed  
30 oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap"

-65-

segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

**[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric Phosphorothioate Oligonucleotides**

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

-66-

**[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides**

5 [2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

10 **[2'-O-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides**

[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above  
15 procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization  
20 utilizing 3,4,5-benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides  
25 are synthesized according to United States patent 5,623,065, herein incorporated by reference.

**Example 6**

**Oligonucleotide Isolation**

30 After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by

-67-

polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by <sup>31</sup>P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* **1991**, *266*, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

#### Example 7

##### Oligonucleotide Synthesis - 96 Well Plate Format

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dithiolane-2-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyl-diisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH<sub>4</sub>OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

-68-

**Example 8****Oligonucleotide Analysis - 96 Well Plate Format**

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

**Example 9****Cell culture and oligonucleotide treatment**

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following four cell types are provided for illustrative purposes, but other cell types can be routinely used.

**T-24 cells:**

The transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and



-69-

dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be  
5 seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 was obtained  
10 from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per  
15 mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

20 Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells were maintained for up  
25 to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville MD). HEKs were routinely maintained in Keratinocyte Growth Medium  
30 (Clonetics Corporation, Walkersville MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

Treatment with antisense compounds:

35 When cells reached 80% confluency, they were treated

-70-

with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200  $\mu$ L OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130  $\mu$ L of OPTI-MEM™-1 containing 3.75  $\mu$ g/mL LIPOFECTIN™ (Gibco BRL) and the desired oligonucleotide at a final concentration of 150 nM. After 4 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16 hours after oligonucleotide treatment.

**Example 10****10 Analysis of oligonucleotide inhibition of MEKK5 expression**

Antisense modulation of MEKK5 expression can be assayed in a variety of ways known in the art. For example, MEKK5 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. Other methods of PCR are also known in the art.

MEKK5 protein levels can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies

-71-

directed to MEKK5 can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

#### Example 11

#### 25 Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200  $\mu$ L cold PBS. 60  $\mu$ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM

- 72 -

vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55  $\mu$ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200  $\mu$ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60  $\mu$ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be  
15 treated similarly, using appropriate volumes of all  
solutions.

### Example 12

## Total RNA Isolation

20 Total mRNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200  $\mu$ L cold  
25 PBS. 100  $\mu$ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100  $\mu$ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a  
30 QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of  
35 the RNEASY 96™ plate and the vacuum applied for a period of

-73-

- 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the
- 5 QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 µL water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 µL water.
- 10 The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are
- 15 carried out.

**Example 13****Real-time Quantitative PCR Analysis of MEKK5 mRNA Levels**

- Quantitation of MEKK5 mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700
- 20 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As
- 25 opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically
- 30 between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE or FAM, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA,
- 35 obtained from either Operon Technologies Inc., Alameda, CA

- 74 -

or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

PCR reagents were obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions were carried out by adding 25  $\mu$ L PCR cocktail (1x TAQMAN™ buffer A, 5.5 mM  $MgCl_2$ , 300  $\mu$ M each of dATP, dCTP and dGTP, 600  $\mu$ M of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25  $\mu$ L poly(A) mRNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension). MEKK5 probes and primers were designed to hybridize to the human MEKK5 sequence, using published sequence information (GenBank

-75-

accession number U67156, incorporated herein as SEQ ID NO:1).

For MEKK5 the PCR primers were:

forward primer: CGGCCAAGAAAAGGAAGCT (SEQ ID NO: 2)

5 reverse primer: CGCCCTGTGCAGAGTTTAGAG (SEQ ID NO: 3) and the PCR probe was: FAM-CCTTCCCGCTCACCCGGCTTC-TAMRA

(SEQ ID NO: 4) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

10 For GAPDH the PCR primers were:

forward primer: GAAGGTGAAGGTCCGAGTC (SEQ ID NO: 5)

reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 6) and the PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (SEQ ID NO: 7) where JOE (PE-Applied Biosystems, Foster City, CA)

15 is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

#### Example 14

##### Northern blot analysis of MEKK5 mRNA levels

Eighteen hours after antisense treatment, cell  
20 monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing  
25 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST "B"  
30 Inc., Friendswood, TX). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, CA).

Membranes were probed using QUICKHYB™ hybridization  
35 solution (Stratagene, La Jolla, CA) using manufacturer's

-76-

recommendations for stringent conditions with a MEKK5 specific probe prepared by PCR using the forward primer CGGCCAAGAAAAGGAAGCT (SEQ ID NO: 2) and the reverse primer CGCCCTGTGCAGAGTTTAGAG (SEQ ID NO: 3). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA). Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

**Example 15****Antisense inhibition of MEKK5 expression- phosphorothioate oligodeoxynucleotides**

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human MEKK5 RNA, using published sequences (GenBank accession number U67156, incorporated herein as SEQ ID NO: 1). The oligonucleotides are shown in Table 1. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. U67156), to which the oligonucleotide binds. All compounds in Table 1 are oligodeoxynucleotides with phosphorothioate backbones (internucleoside linkages) throughout. The compounds were analyzed for effect on MEKK5 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 1

Inhibition of MEKK5 mRNA levels by phosphorothioate oligodeoxynucleotides

ISIS#	REGION	TARGET SITE	SEQUENCE	% Inhibition	SEQ ID NO.
102049	5' UTR	3	cagctcaagggcgccgcgct	41	8
102052	5' UTR	42	gccggctgacaagtcggctc	57	9



WO 01/07461

PCT/US00/19822

-77-

	102054	5' UTR	83	gaagccgggtgagcgggaag	66	10
	102055	5' UTR	169	cgctgcccggcgggcggtcg	22	11
	102057	Start Codon	342	tctctccgggcccgggcagca	0	12
	102059	Start Codon	344	catctctccgggcccgggcag	39	13
5	102061	Start Codon	346	ctcatctctccgggcccgggc	70	14
	102064	Start Codon	348	tgctcatctctccgggcccgg	60	15
	102066	Start Codon	350	cgtgctcatctctccgggcc	88	16
	102067	Start Codon	352	tccgtgctcatctctccggg	83	17
	102070	Start Codon	354	cctccgtgctcatctctccg	91	18
10	102071	Start Codon	356	cgcctccgtgctcatctctc	90	19
	102073	Start Codon	358	tccgcctccgtgctcatctc	88	20
	102076	Start Codon	360	cgtccgcctccgtgctcatc	88	21
	102077	Start Codon	362	ttcgtccgcctccgtgctca	82	22
	102080	Coding	414	ggatgggtgcagaagcccag	50	23
15	102081	Coding	506	ccagaagctgcccggcgggcg	44	24
	102083	Coding	567	cactgctcgaggaggtggcc	53	25
	102086	Coding	677	ggcctcgctctcggccacca	97	26
	102088	Coding	730	agggtttccagggtggcgcc	48	27
	102090	Coding	883	atgttggtggccatgctgaa	69	28
20	102092	Coding	1046	tgtcaacccttcatgaagc	81	29
	102094	Coding	1180	atgtcattgagtatagattc	31	30
	102096	Coding	1355	ttctaaagtctctaccagct	76	31
	102097	Coding	1577	tctgctttcagtgtccgtga	79	32
	102100	Coding	1877	cttgagggtaccatgctggtg	64	33
25	102102	Coding	2007	cagtaacatctgtctttgtg	38	34
	102104	Coding	2193	caaatttagaaataactcact	15	35
	102105	Coding	2391	ctctgtcaccattttcatca	59	36
	102107	Coding	2742	gaactatctgattgtcatgg	17	37
	102110	Coding	2997	ctcccagttcataaaatggg	15	38
30	102112	Coding	3147	catcaacaagcaagtcgtta	63	39
	102113	Coding	3383	ccgaattcccttgacatctc	38	40
	102116	Coding	3633	caaattctctgaggcttgca	46	41
	102118	Coding	4329	accggcttatagtgtcttca	27	42
	102120	Stop Codon	4476	tgagcaacagtcagtcgtgt	44	43

-78-

102121	3' UTR	4526	aagaagatcagctctgtatt	51	44
102123	3' UTR	4590	agtaaacaataactggattt	23	45
102125	3' UTR	4704	tctaattgttcaggattattt	0	46
102128	3' UTR	4829	gcacgatcacatgaatgtta	42	47

5

As shown in Table 1, SEQ ID NOs 8, 9, 10, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 36, 39, 40, 41, 43, 44 and 47 demonstrated at least 35% inhibition of MEKK5 expression in this assay and are therefore preferred.

10

**Example 16:****Antisense inhibition of MEKK5 expression- phosphorothioate 2'-MOE gapmer oligonucleotides**

In accordance with the present invention, a second series of oligonucleotides targeted to human MEKK5 were synthesized. The oligonucleotide sequences are shown in Table 2. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. U67156), to which the oligonucleotide binds.

All compounds in Table 2 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. Cytidine residues in the 2'-MOE wings are 5-methylcytidines.

Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from two experiments. If present, "N.D." indicates "no data".

30

-79-

Table 2

Inhibition of MEKK5 mRNA levels by chimeric  
phosphorothioate oligonucleotides having 2'-MOE wings and a  
deoxy gap

5	ISIS#	REGION	TARGET SITE	SEQUENCE	% Inhibition	SEQ ID NO.
	102130	5' UTR	3	cagctcaagggcgccgcgct	57	8
	102132	5' UTR	42	gccggctgacaagtcggctc	56	9
	102133	5' UTR	83	gaagccgggtgagcgggaag	68	10
10	102135	5' UTR	169	cgctgcccggcggcggtcg	47	11
	102137	Start Codon	342	tctctccgggcccgggcagca	0	12
	102139	Start Codon	344	catctctccgggcccgggcag	65	13
	102142	Start Codon	346	ctcatctctccgggcccgggc	77	14
	102143	Start Codon	348	tgctcatctctccgggcccgg	76	15
15	102145	Start Codon	350	cgtgctcatctctccgggcc	81	16
	102148	Start Codon	352	tccgtgctcatctctccggg	79	17
	102149	Start Codon	354	cctccgtgctcatctctccg	74	18
	102151	Start Codon	356	cgcctccgtgctcatctctc	81	19
	102153	Start Codon	358	tccgcctccgtgctcatctc	64	20
20	102156	Start Codon	360	cgccgcctccgtgctcatc	75	21
	102158	Start Codon	362	ttcgtccgcctccgtgctca	72	22
	102160	Coding	414	ggatggtgcagaagcccag	75	23
	102161	Coding	506	ccagaagctgcccggcg	71	24
	102164	Coding	567	cactgctcgaggaggtggcc	67	25
25	102165	Coding	677	ggcctcgctctcgccacca	79	26
	102168	Coding	730	agggtttccagggtggcgcc	38	27
	102169	Coding	883	atgttggtggccatgctgaa	72	28
	102171	Coding	1046	tgtcaacccttcatgaagc	78	29
	102174	Coding	1180	atgtcattgagtatagattc	77	30
30	102176	Coding	1355	ttctaaagtctctaccagct	70	31
	102177	Coding	1577	tctgctttcagtgtccgtga	62	32
	102179	Coding	1877	cttgaggtaccatgctggtg	65	33
	102181	Coding	2007	cagtaacatctgtctttgtg	55	34
	102184	Coding	2193	caaatttagaaatactcact	21	35

-80-

	102185	Coding	2391	ctctgtcaccattttcatca	68	36
	102187	Coding	2742	gaactatctgattgtcatgg	37	37
	102190	Coding	2997	ctcccagttcataaaatggg	15	38
	102192	Coding	3147	catcaacaagcaagtcgtta	29	39
5	102193	Coding	3383	ccgaattcccttgacatctc	31	40
	102195	Coding	3633	caaattctctgaggcttgca	32	41
	102198	Coding	4329	accggcttatagtgtcttca	16	42
	102200	Stop	4476	tgagcaacagtcaagtctgt	44	43
		Codon				
	102201	3' UTR	4526	aagaagatcagctctgtatt	42	44
10	102203	3' UTR	4590	agtaaacaataactggattt	23	45
	102205	3' UTR	4704	tctaattgttcaggattattt	18	46
	102207	3' UTR	4829	gcacgatcacatgaatgtta	32	47

As shown in Table 2, SEQ ID NOS 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 43 and 44 demonstrated at least 35% inhibition of MEKK5 expression in this experiment and are therefore preferred.

#### Example 17

#### 20 Western blot analysis of MEKK5 protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to MEKK5 is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

-81-

What is claimed is:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human MEKK5, wherein said antisense compound specifically hybridizes with  
5 and inhibits the expression of human MEKK5.

2. The antisense compound of claim 1 which is an antisense oligonucleotide.

3. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO:  
10 8, 9, 10, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 36, 39, 40, 41, 43, 44, 47, 11, 30 or 37.

4. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO:  
15 8, 9, 10, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 36, 43 or 44.

5. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

20 6. The antisense compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.

7. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified  
25 sugar moiety.

8. The antisense compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

9. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified  
30 nucleobase.

10. The antisense compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.

11. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

-82-

12. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. The composition of claim 12 further comprising a colloidal dispersion system.

14. The composition of claim 12 wherein the antisense  
5 compound is an antisense oligonucleotide.

15. A method of inhibiting the expression of MEKK5 in human cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of MEKK5 is inhibited.

10 16. A method of treating a human having a disease or condition associated with MEKK5 comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of MEKK5 is inhibited.

15 17. The method of claim 16 wherein the disease or condition is a hyperproliferative disorder.

18. The method of claim 17 wherein the hyperproliferative disorder is cancer.

19. The method of claim 16 wherein the disease or  
20 condition is an inflammatory disorder.

20. The method of claim 16 wherein the disease or condition is aberrant wound healing.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
1 February 2001 (01.02.2001)

PCT


(10) International Publication Number  
WO 01/07461 A1

- (51) International Patent Classification<sup>7</sup>: C07H 21/04, (74) Agents: LICATA, Jane, Massey et al.; Law Offices of  
A61K 48/00, C12Q 1/68, C12P 19/34 Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053  
(US).
- (21) International Application Number: PCT/US00/19822
- (22) International Filing Date: 20 July 2000 (20.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/359,757 23 July 1999 (23.07.1999) US
- (71) Applicant (for all designated States except US): ISIS  
PHARMACEUTICALS, INC. [US/US]; 2292 Faraday  
Avenue, Carlsbad, CA 92008 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MONIA, Brett, P.  
[US/US]; 7605 Nueva Castilla Way, La Costa, CA 92009  
(US). GAARDE, William, A. [US/US]; 3105 Quebrada  
Circle, Carlsbad, CA 92009 (US). COWSERT, Lex, M.  
[US/US]; 3008 Newshire Street, Carlsbad, CA 92008 (US).
- Published:  
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTISENSE MODULATION OF MEKK5 EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK5. Methods of using these compounds for modulation of MEKK5 expression and for treatment of diseases associated with expression of MEKK5 are provided.

WO 01/07461 A1

Docket No.  
RTSP-0265

# Declaration and Power of Attorney For Patent Application

## English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**Antisense Modulation of MEKK5 Expression**

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 20 July 2000 as United States Application No. or PCT International Application Number PCT/US00/19822 and was amended on \_\_\_\_\_

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐



I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

**09/359,757**

**July 23, 1999**

**Patented**

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Jane Massey Licata, Reg. No. 32,257  
 Kathleen A. Tyrrell, Reg. No. 38,350  
 Laura M. Plunkett, Reg. No. 45,015  
 Bridget C. Sciamanna, Reg. No. 47,333

Herb Boswell, Reg. No. 27,311  
 Laurel Spear Bernstein, Reg. No. 37,280  
 Robert S. Andrews, Reg. No. 44,508  
 Neil S. Bartfeld, Reg. No. 39,901  
 Kenneth H. Tarbet, Reg. No. 43,181  
 Donna T. Ward, Reg. No. 48,271  
 Matthew Grumbling, Reg. No. 44,427  
 of the firm  
 ISIS Pharmaceuticals, Inc.-Carlsbad Research Center  
 2292 Faraday Avenue  
 Carlsbad, California 92008

of the firm

Licata & Tyrrell P.C.  
 66 E. Main Street  
 Marlton, New Jersey 08053

Send Correspondence to:



**26259**

PATENT TRADEMARK OFFICE

Direct Telephone Calls to: (name and telephone number)

Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor

**Brett P. Monia**

Sole or first inventor's signature

*Brett P. Monia*

Date

*5/2/02*

Residence

**Encinitas, California CA**

Citizenship

**US**

Post Office Address

**2306 Casa Hermosa Court**

**Encinitas, California 92024**

Full name of second inventor, if any

**William A. Gaarde**

Second inventor's signature

*William A. Gaarde*

Date

*5/8/02*

Residence

**Carlsbad, California CA**

Citizenship

**US**

Post Office Address

**3105 Quebrada Circle**

**Carlsbad, California 92009**

300  
Full name of third inventor, if any

Lex M. Cowser

Third inventor's signature

Date

4/25/02

Residence

San Mateo, California CA

Citizenship

US

Post Office Address

1299 Parrott Drive

San Mateo, California 94402

Full name of fourth inventor, if any

Fourth inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of fifth inventor, if any

Fifth inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of sixth inventor, if any

Sixth inventor's signature

Date

Residence

Citizenship

Post Office Address

WO 01/07461

PCT/US00/19822

## SEQUENCE LISTING

<110> Brett P. Monia  
William Gaarde  
Lex M. Cowser  
ISIS PHARMACEUTICALS, INC.

<120> ANTISENSE MODULATION OF MEKK5 EXPRESSION

<130> RTSP-0066

<150> 09/359,757

<151> 1999-07-23

<160> 47

<210> 1

<211> 5236

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (361)..(4485)

<400> 1

<220>

<221> unsure

<222> 4687

<223> unknown

```

cgagcgcggc gcccttgagc tgcaccgcgg cgcaggtttg cgagccgact tgtcagccgg      60
ccaagaaaag gaagctccgt cccttcccgc tcacccggct tccccacccc ttgtactcta      120
aactctgcac agggcgagcg gcgcggccac tgatgcgccg aggaggagcg agccgccgcc      180
gggcagcggc gtgccctcgg gggagagggc gccggataag agcggcggcg cggcggcgat      240
ggcgcggcgc gcgatggcag ctgcttagcc cggcggggcg ggagcagccc cgagctgtgg      300
ctggccaggc ggtgcggctg ggcggggggc gccgccggcg ttgctgcccg gcccggagag      360
atg agc acg gag gcg gac gaa ggc atc act ttc tct gtg cca ccc ttc      408
Met Ser Thr Glu Ala Asp Glu Gly Ile Thr Phe Ser Val Pro Pro Phe
   1             5             10             15

gcc ccc tcg ggc ttc tgc acc atc ccc gag ggc ggc atc tgc agg agg      456
Ala Pro Ser Gly Phe Cys Thr Ile Pro Glu Gly Gly Ile Cys Arg Arg
           20             25             30

gga gga gcg gcg gcg gtg ggc gag ggc gag gag cac cag ctg cca ccg      504
Gly Gly Ala Ala Ala Val Gly Glu Gly Glu Glu His Gln Leu Pro Pro
           35             40             45

ccg ccg ccg ggc agc ttc tgg aac gtg gag agc gcc gct gcc cct ggc      552
Pro Pro Pro Gly Ser Phe Trp Asn Val Glu Ser Ala Ala Ala Pro Gly
           50             55             60

atc ggt tgt ccg gcg gcc acc tcc tcg agc agt gcc acc cga ggc cgg      600
Ile Gly Cys Pro Ala Ala Thr Ser Ser Ser Ser Ala Thr Arg Gly Arg
   65             70             75             80

```

WO 01/07461

PCT/US00/19822

ggc agc tct gtt ggc ggg ggc agc cga cgg acc acg gtg gca tat gtg Gly Ser Ser Val Gly Gly Ser Arg Arg Thr Thr Val Ala Tyr Val 85 90 95	648
atc aac gaa gcg agc caa ggg caa ctg gtg gtg gcc gag agc gag gcc Ile Asn Glu Ala Ser Gln Gly Gln Leu Val Val Ala Glu Ser Glu Ala 100 105 110	696
ctg cag agc ttg cgg gag gcg tgc gag aca gtg ggc gcc acc ctg gaa Leu Gln Ser Leu Arg Glu Ala Cys Glu Thr Val Gly Ala Thr Leu Glu 115 120 125	744
acc ctg cat ttt ggg aaa ctc gac ttt gga gaa acc acc gtg ctg gac Thr Leu His Phe Gly Lys Leu Asp Phe Gly Glu Thr Thr Val Leu Asp 130 135 140	792
cgc ttt tac aat gca gat att gcg gtg gtg gag atg agc gat gcc ttc Arg Phe Tyr Asn Ala Asp Ile Ala Val Val Glu Met Ser Asp Ala Phe 145 150 155 160	840
cgg cag ccg tcc ttg ttt tac cac ctt ggg gtg aga gaa agt ttc agc Arg Gln Pro Ser Leu Phe Tyr His Leu Gly Val Arg Glu Ser Phe Ser 165 170 175	888
atg gcc aac aac atc atc ctc tac tgt gat act aac tcg gac tct ctg Met Ala Asn Asn Ile Ile Leu Tyr Cys Asp Thr Asn Ser Asp Ser Leu 180 185 190	936
cag tca ctg aag gaa ata att tgc cag aag aat act atg tgc act ggg Gln Ser Leu Lys Glu Ile Ile Cys Gln Lys Asn Thr Met Cys Thr Gly 195 200 205	984
aac tac acc ttt gtt cct tac atg ata act cca cat aac aaa gtc tac Asn Tyr Thr Phe Val Pro Tyr Met Ile Thr Pro His Asn Lys Val Tyr 210 215 220	1032
tgc tgt gac agc agc ttc atg aag ggg ttg aca gag ctc atg caa ccg Cys Cys Asp Ser Ser Phe Met Lys Gly Leu Thr Glu Leu Met Gln Pro 225 230 235 240	1080
aac ttc gag ctg ctt ctt gga ccc atc tgc tta cct ctt gtg gat cgt Asn Phe Glu Leu Leu Leu Gly Pro Ile Cys Leu Pro Leu Val Asp Arg 245 250 255	1128
ttt att caa ctt ttg aag gtg gca caa gca agt tct agc cag tac ttc Phe Ile Gln Leu Leu Lys Val Ala Gln Ala Ser Ser Ser Gln Tyr Phe 260 265 270	1176
cgg gaa tct ata ctc aat gac atc agg aaa gct cgt aat tta tac act Arg Glu Ser Ile Leu Asn Asp Ile Arg Lys Ala Arg Asn Leu Tyr Thr 275 280 285	1224
ggc aaa gaa ttg gca gct gag ttg gca aga att cgg cag cga gta gat Gly Lys Glu Leu Ala Ala Glu Leu Ala Arg Ile Arg Gln Arg Val Asp 290 295 300	1272
aat atc gaa gtc ttg aca gca gat att gtc ata aat ctg tta ctt tcc Asn Ile Glu Val Leu Thr Ala Asp Ile Val Ile Asn Leu Leu Leu Ser 305 310 315 320	1320
tac aga gat atc cag gac tat gat tct att gtg aag ctg gta gag act Tyr Arg Asp Ile Gln Asp Tyr Asp Ser Ile Val Lys Leu Val Glu Thr 330 335 340	1368

WO 01/07461

PCT/US00/19822

325										330					335					
tta	gaa	aaa	ctg	cca	acc	ttt	gat	ttg	gcc	tcc	cat	cac	cat	gtg	aag	1416				
Leu	Glu	Lys	Leu	Pro	Thr	Phe	Asp	Leu	Ala	Ser	His	His	His	Val	Lys					
			340							345				350						
ttt	cat	tat	gca	ttt	gca	ctg	aat	agg	aga	aat	ctc	cct	ggg	gac	aga	1464				
Phe	His	Tyr	Ala	Phe	Ala	Leu	Asn	Arg	Arg	Asn	Leu	Pro	Gly	Asp	Arg					
			355							360				365						
gca	aaa	gct	ctt	gat	att	atg	att	ccc	atg	gtg	caa	agc	gaa	gga	caa	1512				
Ala	Lys	Ala	Leu	Asp	Ile	Met	Ile	Pro	Met	Val	Gln	Ser	Glu	Gly	Gln					
			370							375				380						
gtt	gct	tca	gat	atg	tat	tgc	cta	gtt	ggg	cga	atc	tac	aaa	gat	atg	1560				
Val	Ala	Ser	Asp	Met	Tyr	Cys	Leu	Val	Gly	Arg	Ile	Tyr	Lys	Asp	Met					
			385							390				395						
ttt	ttg	gac	tct	aat	ttc	acg	gac	act	gaa	agc	aga	gac	cat	gga	gct	1608				
Phe	Leu	Asp	Ser	Asn	Phe	Thr	Asp	Thr	Glu	Ser	Arg	Asp	His	Gly	Ala					
			405							410				415						
tct	tgg	ttc	aaa	aag	gca	ttt	gaa	tct	gag	cca	aca	cta	cag	tca	gga	1656				
Ser	Trp	Phe	Lys	Lys	Ala	Phe	Glu	Ser	Glu	Pro	Thr	Leu	Gln	Ser	Gly					
			420							425				430						
att	aat	tat	gcg	gtc	ctc	ctc	ctg	gca	gct	gga	cac	cag	ttt	gaa	tct	1704				
Ile	Asn	Tyr	Ala	Val	Leu	Leu	Leu	Ala	Ala	Gly	His	Gln	Phe	Glu	Ser					
			435							440				445						
tcc	ttt	gag	ctc	cgg	aaa	gtt	ggg	gtg	aag	cta	agt	agt	ctt	ctt	ggg	1752				
Ser	Phe	Glu	Leu	Arg	Lys	Val	Gly	Val	Lys	Leu	Ser	Ser	Leu	Leu	Gly					
			450							455				460						
aaa	aag	gga	aac	ttg	gaa	aaa	ctc	cag	agc	tac	tgg	gaa	gtt	gga	ttt	1800				
Lys	Lys	Gly	Asn	Leu	Glu	Lys	Leu	Gln	Ser	Tyr	Trp	Glu	Val	Gly	Phe					
			465							470				475						
ttt	ctg	ggg	gcc	agc	gtc	cta	gcc	aat	gac	cac	atg	aga	gtc	att	caa	1848				
Phe	Leu	Gly	Ala	Ser	Val	Leu	Ala	Asn	Asp	His	Met	Arg	Val	Ile	Gln					
			485							490				495						
gca	tct	gaa	aag	ctt	ttt	aaa	ctg	aag	aca	cca	gca	tgg	tac	ctc	aag	1896				
Ala	Ser	Glu	Lys	Leu	Phe	Lys	Leu	Lys	Thr	Pro	Ala	Trp	Tyr	Leu	Lys					
			500							505				510						
tct	att	gta	gag	aca	att	tta	ata	tat	aag	cat	ttt	gtg	aaa	ctg	acc	1944				
Ser	Ile	Val	Glu	Thr	Ile	Leu	Ile	Tyr	Lys	His	Phe	Val	Lys	Leu	Thr					
			515							520				525						
aca	gaa	cag	cct	gtg	gcc	aag	caa	gaa	ctt	gtg	gac	ttt	tgg	atg	gat	1992				
Thr	Glu	Gln	Pro	Val	Ala	Lys	Gln	Glu	Leu	Val	Asp	Phe	Trp	Met	Asp					
			530							535				540						
ttc	ctg	gtc	gag	gcc	aca	aag	aca	gat	gtt	act	gtg	gtt	agg	ttt	cca	2040				
Phe	Leu	Val	Glu	Ala	Thr	Lys	Thr	Asp	Val	Thr	Val	Val	Arg	Phe	Pro					
			545							550				555						
gta	tta	ata	tta	gaa	cca	acc	aaa	atc	tat	caa	cct	tct	tat	ttg	tct	2088				
Val	Leu	Ile	Leu	Glu	Pro	Thr	Lys	Ile	Tyr	Gln	Pro	Ser	Tyr	Leu	Ser					
			565							570				575						
atc	aac	aat	gaa	gtt	gag	gaa	aag	aca	atc	tct	att	tgg	cac	gtg	ctt	2136				

WO 01/07461

PCT/US00/19822

Ile	Asn	Asn	Glu	Val	Glu	Glu	Lys	Thr	Ile	Ser	Ile	Trp	His	Val	Leu		
			580					585					590				
cct	gat	gac	aag	aaa	ggt	ata	cat	gag	tgg	aat	ttt	agt	gcc	tct	tct	2184	
Pro	Asp	Asp	Lys	Lys	Gly	Ile	His	Glu	Trp	Asn	Phe	Ser	Ala	Ser	Ser		
			595				600					605					
gtc	agg	gga	gtg	agt	att	tct	aaa	ttt	gaa	gaa	aga	tgc	tgc	ttt	ctt	2232	
Val	Arg	Gly	Val	Ser	Ile	Ser	Lys	Phe	Glu	Glu	Arg	Cys	Cys	Phe	Leu		
	610					615					620						
tat	gtg	ctt	cac	aat	tct	gat	gat	ttc	caa	atc	tat	ttc	tgt	aca	gaa	2280	
Tyr	Val	Leu	His	Asn	Ser	Asp	Asp	Phe	Gln	Ile	Tyr	Phe	Cys	Thr	Glu		
	625				630					635					640		
ctt	cat	tgt	aaa	aag	ttt	ttt	gag	atg	gtg	aac	acc	att	acc	gaa	gag	2328	
Leu	His	Cys	Lys	Lys	Phe	Phe	Glu	Met	Val	Asn	Thr	Ile	Thr	Glu	Glu		
				645				650					655				
aag	ggg	aga	agc	aca	gag	gaa	gga	gac	tgt	gaa	agt	gac	ttg	ctg	gag	2376	
Lys	Gly	Arg	Ser	Thr	Glu	Glu	Gly	Asp	Cys	Glu	Ser	Asp	Leu	Leu	Glu		
			660					665					670				
tat	gac	tat	gaa	tat	gat	gaa	aat	ggt	gac	aga	gtc	gtt	tta	gga	aaa	2424	
Tyr	Asp	Tyr	Glu	Tyr	Asp	Glu	Asn	Gly	Asp	Arg	Val	Val	Val	Gly	Lys		
			675				680					685					
ggc	act	tat	ggg	ata	gtc	tac	gca	ggt	cgg	gac	ttg	agc	aac	caa	gtc	2472	
Gly	Thr	Tyr	Gly	Ile	Val	Tyr	Ala	Gly	Arg	Asp	Leu	Ser	Asn	Gln	Val		
	690					695					700						
aga	att	gct	att	aag	gaa	atc	cca	gag	aga	gac	agc	aga	tac	tct	cag	2520	
Arg	Ile	Ala	Ile	Lys	Glu	Ile	Pro	Glu	Arg	Asp	Ser	Arg	Tyr	Ser	Gln		
	705				710					715					720		
ccc	ctg	cat	gaa	gaa	ata	gca	ttg	cat	aaa	cac	ctg	aag	cac	aaa	aat	2568	
Pro	Leu	His	Glu	Glu	Ile	Ala	Leu	His	Lys	His	Leu	Lys	His	Lys	Asn		
				725					730					735			
att	gtc	cag	tat	ctg	ggc	tct	ttc	agt	gag	aat	ggt	ttc	att	aaa	atc	2616	
Ile	Val	Gln	Tyr	Leu	Gly	Ser	Phe	Ser	Glu	Asn	Gly	Phe	Ile	Lys	Ile		
			740					745					750				
ttc	atg	gag	cag	gtc	cct	gga	gga	agt	ctt	tct	gct	ctc	ctt	cgt	tcc	2664	
Phe	Met	Glu	Gln	Val	Pro	Gly	Gly	Ser	Leu	Ser	Ala	Leu	Leu	Arg	Ser		
		755					760					765					
aaa	tgg	ggt	cca	tta	aaa	gac	aat	gag	caa	aca	att	ggc	ttt	tat	aca	2712	
Lys	Trp	Gly	Pro	Leu	Lys	Asp	Asn	Glu	Gln	Thr	Ile	Gly	Phe	Tyr	Thr		
		770				775					780						
aag	caa	ata	ctg	gaa	gga	tta	aaa	tat	ctc	cat	gac	aat	cag	ata	gtt	2760	
Lys	Gln	Ile	Leu	Glu	Gly	Leu	Lys	Tyr	Leu	His	Asp	Asn	Gln	Ile	Val		
	785				790					795					800		
cac	cgg	gac	ata	aag	ggt	gac	aat	gtg	ttg	att	aat	acc	tac	agt	ggt	2808	
His	Arg	Asp	Ile	Lys	Gly	Asp	Asn	Val	Leu	Ile	Asn	Thr	Tyr	Ser	Gly		
				805					810					815			
gtt	ctc	aag	atc	tct	gac	ttc	gga	aca	tca	aag	agg	ctt	gct	ggc	ata	2856	
Val	Leu	Lys	Ile	Ser	Asp	Phe	Gly	Thr	Ser	Lys	Arg	Leu	Ala	Gly	Ile		
			820					825						830			

WO 01/07461

PCT/US00/19822

aac ccc tgt act gaa act ttt act ggt acc ctc cag tat atg gca cca	2904
Asn Pro Cys Thr Glu Thr Phe Thr Gly Thr Leu Gln Tyr Met Ala Pro	
835 840 845	
gaa ata ata gat aaa gga cca aga ggc tac gga aaa gca gca gac atc	2952
Glu Ile Ile Asp Lys Gly Pro Arg Gly Tyr Gly Lys Ala Ala Asp Ile	
850 855 860	
tgg tct ctg ggc tgt aca atc att gaa atg gcc aca gga aaa ccc cca	3000
Trp Ser Leu Gly Cys Thr Ile Ile Glu Met Ala Thr Gly Lys Pro Pro	
865 870 875 880	
ttt tat gaa ctg gga gaa cca caa gca gct atg ttc aag gtg gga atg	3048
Phe Tyr Glu Leu Gly Glu Pro Gln Ala Ala Met Phe Lys Val Gly Met	
885 890 895	
ttt aaa gtc cac cct gag atc cca gag tcc atg tct gca gag gcc aag	3096
Phe Lys Val His Pro Glu Ile Pro Glu Ser Met Ser Ala Glu Ala Lys	
900 905 910	
gca ttc ata ctg aaa tgt ttt gaa cca gat cct gac aag aga gcc tgt	3144
Ala Phe Ile Leu Lys Cys Phe Glu Pro Asp Pro Asp Lys Arg Ala Cys	
915 920 925	
gct aac gac ttg ctt gtt gat gag ttt tta aaa gtt tca agc aaa aag	3192
Ala Asn Asp Leu Leu Val Asp Glu Phe Leu Lys Val Ser Ser Lys Lys	
930 935 940	
aaa aag aca caa cct aag ctt tca gct ctt tca gct gga tca aat gaa	3240
Lys Lys Thr Gln Pro Lys Leu Ser Ala Leu Ser Ala Gly Ser Asn Glu	
945 950 955 960	
tat ctc agg agt ata tcc ttg ccg gta cct gtg ctg gtg gag gac acc	3288
Tyr Leu Arg Ser Ile Ser Leu Pro Val Pro Val Leu Val Glu Asp Thr	
965 970 975	
agc agc agc agt gag tac ggc tca gtt tca ccc gac acg gag ttg aaa	3336
Ser Ser Ser Ser Glu Tyr Gly Ser Val Ser Pro Asp Thr Glu Leu Lys	
980 985 990	
gtg gac ccc ttc tct ttc aaa aca aga gcc aag tcc tgc gga gaa aga	3384
Val Asp Pro Phe Ser Phe Lys Thr Arg Ala Lys Ser Cys Gly Glu Arg	
995 1000 1005	
gat gtc aag gga att cgg aca ctc ttt ttg ggc att cca gat gag aat	3432
Asp Val Lys Gly Ile Arg Thr Leu Phe Leu Gly Ile Pro Asp Glu Asn	
1010 1015 1020	
ttt gaa gat cac agt gct cct cct tcc cct gaa gaa aaa gat tct gga	3480
Phe Glu Asp His Ser Ala Pro Pro Ser Pro Glu Glu Lys Asp Ser Gly	
1025 1030 1035 1040	
ttc ttc atg ctg agg aag gac agt gag agg cga gct acc ctt cac agg	3528
Phe Phe Met Leu Arg Lys Asp Ser Glu Arg Arg Ala Thr Leu His Arg	
1045 1050 1055	
atc ctg acg gaa gac caa gac aaa att gtg aga aac cta atg gaa tct	3576
Ile Leu Thr Glu Asp Gln Asp Lys Ile Val Arg Asn Leu Met Glu Ser	
1060 1065 1070	
tta gct cag ggg gct gaa gaa ccg aaa cta aaa tgg gaa cac atc aca	3624
Leu Ala Gln Gly Ala Glu Glu Pro Lys Leu Lys Trp Glu His Ile Thr	
1075 1080 1085	



WO 01/07461

PCT/US00/19822

acc ctc att gca agc ctc aga gaa ttt gtg aga tcc act gac cga aaa	3672
Thr Leu Ile Ala Ser Leu Arg Glu Phe Val Arg Ser Thr Asp Arg Lys	
1090 1095 1100	
atc ata gcc acc aca ctg tca aag ctg aaa ctg gag ctg gac ttc gac	3720
Ile Ile Ala Thr Thr Leu Ser Lys Leu Lys Leu Glu Leu Asp Phe Asp	
1105 1110 1115 1120	
agc cat ggc att agc caa gtc cag gtg gta ctc ttt ggt ttt caa gat	3768
Ser His Gly Ile Ser Gln Val Gln Val Val Leu Phe Gly Phe Gln Asp	
1125 1130 1135	
gct gtc aat aaa gtt ctt cgg aat cat aac atc aag ccg cac tgg atg	3816
Ala Val Asn Lys Val Leu Arg Asn His Asn Ile Lys Pro His Trp Met	
1140 1145 1150	
ttt gcc tta gac agt atc att cgg aag gcg gta cag aca gcc att acc	3864
Phe Ala Leu Asp Ser Ile Ile Arg Lys Ala Val Gln Thr Ala Ile Thr	
1155 1160 1165	
atc ctg gtt cca gaa cta agg cca cat ttc agc ctt gca tct gag agt	3912
Ile Leu Val Pro Glu Leu Arg Pro His Phe Ser Leu Ala Ser Glu Ser	
1170 1175 1180	
gat act gct gat caa gaa gac ttg gat gta gaa gat gac cat gag gaa	3960
Asp Thr Ala Asp Gln Glu Asp Leu Asp Val Glu Asp Asp His Glu Glu	
1185 1190 1195 1200	
cag cct tca aat caa act gtc cga aga cct cag gct gtc att gaa gat	4008
Gln Pro Ser Asn Gln Thr Val Arg Arg Pro Gln Ala Val Ile Glu Asp	
1205 1210 1215	
gct gtg gct acc tca ggc gtg agc acg ctc agt tct act gtg tct cat	4056
Ala Val Ala Thr Ser Gly Val Ser Thr Leu Ser Ser Thr Val Ser His	
1220 1225 1230	
gat tcc cag agt gct cac cgg tca ctg aat gta cag ctt gga agg atg	4104
Asp Ser Gln Ser Ala His Arg Ser Leu Asn Val Gln Leu Gly Arg Met	
1235 1240 1245	
aaa ata gaa acc aat aga tta ctg gaa gaa ttg gtt cgg aaa gag aaa	4152
Lys Ile Glu Thr Asn Arg Leu Leu Glu Glu Leu Val Arg Lys Glu Lys	
1250 1255 1260	
gaa tta caa gca ctc ctt cat cga gct att gaa gaa aaa gac caa gaa	4200
Glu Leu Gln Ala Leu Leu His Arg Ala Ile Glu Glu Lys Asp Gln Glu	
1265 1270 1275 1280	
att aaa cac ctg aag ctt aag tcc caa ccc ata gaa att cct gaa ttg	4248
Ile Lys His Leu Lys Leu Lys Ser Gln Pro Ile Glu Ile Pro Glu Leu	
1285 1290 1295	
cct gta ttt cat cta aat tct tct ggc aca aat act gaa gat tct gaa	4296
Pro Val Phe His Leu Asn Ser Ser Gly Thr Asn Thr Glu Asp Ser Glu	
1300 1305 1310	
ctt acc gac tgg ctg aga gtg aat gga gct gat gaa gac act ata agc	4344
Leu Thr Asp Trp Leu Arg Val Asn Gly Ala Asp Glu Asp Thr Ile Ser	
1315 1320 1325	
cgg ttt ttg gct gaa gat tat aca cta ttg gat gtt ctc tac tat gtt	4392
Arg Phe Leu Ala Glu Asp Tyr Thr Leu Leu Asp Val Leu Tyr Tyr Val	
1330 1335 1340	



WO 01/07461

PCT/US00/19822

&lt;400&gt; 3

cgccctgtgc agagtttaga g

21

&lt;210&gt; 4

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; PCR Probe

&lt;400&gt; 4

ccttcccgt caccggctt c

21

&lt;210&gt; 5

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; PCR Primer

&lt;400&gt; 5

gaaggtgaag gtcggagtc

19

&lt;210&gt; 6

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; PCR Primer

&lt;400&gt; 6

gaagatggtg atgggatttc

20

&lt;210&gt; 7

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

WO 01/07461

PCT/US00/19822

<223> PCR Probe

<400> 7

caagcttccc gttctcagcc

20

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 8

cagctcaagg gcgccgcgct

20

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 9

gccggctgac aagtcggctc

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 10

gaagccgggt gagcggaag

20

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 11

cgctgcccg cggcggctcg

20

<210> 12

<211> 20

**<212> DNA**

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 12

tctctccggg ccgggagca

20

<210> 13

<211> 20

<212> DNA

### <213> Artificial Sequence

### <223> Antisense Oligonucleotide

<400> 13

catctctccg ggccgggag

20

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 14

ctcatctctc cgggccgggc

20

<210> 15

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 15

tgctcatctc tccgggcccgg

20

<210> 16

<211> 20

**<212> DNA**

<213> Artificial Sequence

## <223> Antisense Oligonucleotide

<400> 16

cgtgctcatc tctccgggcc

20

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

## <223> Antisense Oligonucleotide

<400> 17

tccgtgctca tctctccggg

20

<210> 18

<211> 20

<212> DNA

### <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 18

cctccgtgct catctctccg

20

WO 01/07461

PCT/US00/19822

&lt;210&gt; 19

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 19

cgcctccgtg ctcattcttc

20

&lt;210&gt; 20

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 20

tccgcctccg tgctcatttc

20

&lt;210&gt; 21

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 21

cgtccgcctc cgtgctcatt

20

&lt;210&gt; 22

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 22

ttcgtccgcc tccgtgctca

20

WO 01/07461

PCT/US00/19822

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 23

ggatggtgca gaagcccgag

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 24

ccagaagctg cccggcggcg

20

<210> 25

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 25

cactgctcga ggaggtggcc

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 26



WO 01/07461

PCT/US00/19822

ggcctcgtc tcggccacca

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 27

agggtttcca gggaggcgcc

20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 28

atgttggtgg ccatgctgaa

20

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 29

tgtcaacccc ttcatgaagc

20

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

WO 01/07461

PCT/US00/19822

<400> 30  
atgtcattga gtatagattc 20

<210> 31  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 31  
ttctaaagtc tctaccagct 20

<210> 32  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 32  
tctgctttca gtgtccgtga 20

<210> 33  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 33  
cttgaggtag catgctggtg 20

<210> 34  
<211> 20  
<212> DNA  
<213> Artificial Sequence

WO 01/07461

PCT/US00/19822

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 34

cagtaacatc tgtctttgtg

20

&lt;210&gt; 35

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 35

caaatttaga aatactcact

20

&lt;210&gt; 36

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 36

ctctgtcacc attttcatca

20

&lt;210&gt; 37

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 37

gaactatctg attgtcatgg

20

&lt;210&gt; 38

&lt;211&gt; 20

&lt;212&gt; DNA



WO 01/07461

PCT/US00/19822

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 42

accggcttat agtgtcttca

20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 43

tgagcaacag tcaagtctgt

20

<210> 44

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 44

aagaagatca gctctgtatt

20

<210> 45

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 45

agtaaacaaa tactggattt

20

